These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29784451)

  • 41. Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
    Rodriguez CP; Adelstein DJ; Rybicki LA; Saxton JP; Lorenz RR; Wood BG; Scharpf J; Ives DI
    Head Neck; 2012 Nov; 34(11):1517-23. PubMed ID: 22180262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
    Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determinants of complications and outcome in high-risk squamous cell head-and-neck cancer treated with perioperative high-dose rate brachytherapy (PHDRB).
    Martínez-Monge R; Pagola Divassón M; Cambeiro M; Gaztañaga M; Moreno M; Arbea L; Montesdeoca N; Alcalde J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e245-54. PubMed ID: 21620582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hyperfractionated or Accelerated Hyperfractionated Re-irradiation with ≥42 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer.
    Rades D; Bartscht T; Idel C; Schild SE; Hakim SG
    Anticancer Res; 2018 Jun; 38(6):3653-3656. PubMed ID: 29848723
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
    Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
    Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series.
    Megahed R; Prabhu AV; Mack DP; Gholami S; Samanta S; Patel M; Lewis GD
    Oral Oncol; 2024 May; 152():106778. PubMed ID: 38555751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial.
    Eekers DBP; Roelofs E; Jelen U; Kirk M; Granzier M; Ammazzalorso F; Ahn PH; Janssens GORJ; Hoebers FJP; Friedmann T; Solberg T; Walsh S; Troost EGC; Kaanders JHAM; Lambin P
    Radiother Oncol; 2016 Dec; 121(3):387-394. PubMed ID: 27639891
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses.
    Takiar V; Garden AS; Ma D; Morrison WH; Edson M; Zafereo ME; Gunn GB; Fuller CD; Beadle B; Frank SJ; William WN; Kies M; El-Naggar AK; Weber R; Rosenthal DI; Phan J
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1117-31. PubMed ID: 27354127
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
    Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
    Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
    Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
    Tiwari S; Goel V; John MC; Patnaik N; Doval DC
    Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
    Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
    Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study.
    Comet B; Kramar A; Faivre-Pierret M; Dewas S; Coche-Dequeant B; Degardin M; Lefebvre JL; Lacornerie T; Lartigau EF
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):203-9. PubMed ID: 22331006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck.
    Ward MC; Lee NY; Caudell JJ; Zajichek A; Awan MJ; Koyfman SA; Dunlap NE; Zakem SJ; Hassanzadeh C; Marcrom S; Boggs DH; Isrow D; Vargo JA; Heron DE; Siddiqui F; Bonner JA; Beitler JJ; Yao M; Trotti AM; Riaz N;
    Oral Oncol; 2019 Mar; 90():80-86. PubMed ID: 30846182
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity.
    Lau H; Brar S; Hao D; MacKinnon J; Yee D; Gluck S
    Head Neck; 2006 Mar; 28(3):189-96. PubMed ID: 16265658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of multimodality treatment on overall survival for patients with metastatic or recurrent HPV-positive head and neck squamous cell carcinoma.
    Deeken JF; Newkirk K; Harter KW; Marshall MB; Banovac F; Johnson L; Wang H; Wang Y; Zhuang T; Jay AK; Berkowitz F; Esposito G; Kallakury B; Davidson B
    Head Neck; 2015 May; 37(5):630-5. PubMed ID: 24616038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
    Elbers JBW; Al-Mamgani A; van den Brekel MWM; Jóźwiak K; de Boer JP; Lohuis PJFM; Willems SM; Verheij M; Zuur CL
    Otolaryngol Head Neck Surg; 2019 Jun; 160(6):1023-1033. PubMed ID: 30526317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse skin reactions during treatment with cetuximab plus radiotherapy: Multidisciplinary approach to minimize radio-chemotherapy interruption.
    Ricci F; Paradisi A; Silveri SL; Sampogna F; Miccichè F; Bonomo PL; DiNapoli N; Valentini V; Capizzi R; Guerriero C
    J Dermatolog Treat; 2015 Apr; 26(2):183-7. PubMed ID: 24852820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
    Le QT; Taira A; Budenz S; Jo Dorie M; Goffinet DR; Fee WE; Goode R; Bloch D; Koong A; Martin Brown J; Pinto HA
    Cancer; 2006 May; 106(9):1940-9. PubMed ID: 16532436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.